242 related articles for article (PubMed ID: 32734668)
21. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
Shimoda K; Takahashi N; Kirito K; Iriyama N; Kawaguchi T; Kizaki M
Int J Hematol; 2020 Sep; 112(3):268-291. PubMed ID: 32783166
[No Abstract] [Full Text] [Related]
22. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
23. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
[TBL] [Abstract][Full Text] [Related]
24. Kinase inhibitors in chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Clin Adv Hematol Oncol; 2006 May; 4(5):365-74. PubMed ID: 16728945
[TBL] [Abstract][Full Text] [Related]
25. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
[TBL] [Abstract][Full Text] [Related]
26. [Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Burchert A; Neubauer A
Internist (Berl); 2011 Mar; 52(3):283-93; quiz 294-5. PubMed ID: 21253680
[TBL] [Abstract][Full Text] [Related]
27. Current status and novel strategy of CML.
Morita K; Sasaki K
Int J Hematol; 2021 May; 113(5):624-631. PubMed ID: 33782818
[TBL] [Abstract][Full Text] [Related]
28. Optimizing tolerability of TKI therapy in CML.
Hochhaus A
Blood; 2014 Feb; 123(9):1284-5. PubMed ID: 24578491
[No Abstract] [Full Text] [Related]
29. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Klyuchnikov E; Schafhausen P; Kröger N; Brummendorf TH; Osanmaz O; Asenova S; Zabelina T; Ocheni S; Ayuk F; Zander AR; Bacher U
Acta Haematol; 2009; 122(1):6-10. PubMed ID: 19602874
[No Abstract] [Full Text] [Related]
30. Bosutinib in the treatment of chronic myelogenous leukemia.
Cortes J
Clin Adv Hematol Oncol; 2012 Nov; 10(11):736-7. PubMed ID: 23271260
[No Abstract] [Full Text] [Related]
31. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
[TBL] [Abstract][Full Text] [Related]
32. A second-generation TKI should always be used as initial therapy for CML.
Cortes JE
Blood Adv; 2018 Dec; 2(24):3653-3655. PubMed ID: 30587494
[TBL] [Abstract][Full Text] [Related]
33. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
Claudiani S; Apperley JF; Szydlo R; Khan A; Nesr G; Hayden C; J Innes A; Dominy K; Foskett P; Foroni L; Khorashad J; Milojkovic D
Br J Haematol; 2021 Apr; 193(2):346-355. PubMed ID: 33368155
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
35. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Thienelt CD; Green K; Bowles DW
Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
[TBL] [Abstract][Full Text] [Related]
36. What is new in chronic myeloid leukaemia?
Heaney NB; Holyoake TL
Scott Med J; 2007 Feb; 52(1):36-41; quiz 42, 58. PubMed ID: 17373424
[TBL] [Abstract][Full Text] [Related]
37. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
38. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Quintás-Cardama A; Kantarjian H; Cortes J
Drugs Today (Barc); 2012 Mar; 48(3):177-88. PubMed ID: 22462037
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review.
Szakács Z; Hegyi PJ; Farkas N; Hegyi P; Balaskó M; Erős A; Szujó S; Pammer J; Mosdósi B; Simon M; Nagy A; Für G; Hussain A
PLoS One; 2020; 15(12):e0243045. PubMed ID: 33270732
[TBL] [Abstract][Full Text] [Related]
40. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]